These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Antiemetic efficacy of alprazolam in the combination of metoclopramide plus methylprednisolone. Double-blind randomized crossover study in patients with cisplatin-induced emesis.
    Author: Mori K, Saito Y, Tominaga K.
    Journal: Am J Clin Oncol; 1993 Aug; 16(4):338-41. PubMed ID: 8392288.
    Abstract:
    The usefulness of alprazolam (minor tranquilizer) used in combination with metoclopramide plus methylprednisolone for the prevention and control of emesis induced by chemotherapies, including 5-day continuous intravenous infusion of cisplatin (25 mg/m2/day) for advanced lung cancer, was evaluated using a double-blind randomized crossover design. In our study, 34 cases could be evaluated. No nausea was observed in 14 patients given alprazolam and 4 placebo (p < .01). The mean number of vomiting episodes was significantly smaller in the alprazolam group (1.31 +/- 2.61 vs 2.89 +/- 4.59 times) (p < .01). The mean duration of nausea and vomiting was significantly shorter in the alprazolam group (p < .001 and p < .01). From these findings, it can be concluded that the coadministration of alprazolam is effective in preventing and controlling chemotherapy-induced emesis due to 5-day continuous intravenous infusion of cisplatin in which mental and psychological factors are involved.
    [Abstract] [Full Text] [Related] [New Search]